Randall J. Weisenburger
Analyst
Thank you, John. It has certainly been an eventful quarter with the announcement of the merger and all of the activities that it's involved. That said, I wouldn't want the upcoming merger to distract from the excellent performance Omnicom's agencies had this quarter and through the first 9 months of this year. To make our financial presentation easier to follow, we've added a third column of numbers labeled Non-GAAP. This column excludes the incremental costs we've incurred in the third quarter related to the merger. These costs, which are predominantly professional fees, totaled $28.1 million and net of taxes, reduced EPS by $0.08 per share. As you all know, we do not typically present non-GAAP results, but in this case, we think it will help to evaluate the relative performance of our operations. For the presentation, I will focus my comments on the Non-GAAP column, but we have the reported GAAP numbers side by side for easy reference and clarity. Again, the only difference between the GAAP and non-GAAP results are the exclusion of the merger-related costs and then the follow-on effects on taxes and obviously, the summary numbers, like net income and EPS. So moving on. On the revenue front, as John said, our agencies are continuing to have a good year despite the relatively weak economic environment. In the third quarter, revenue came in at just under $3.5 billion. Total growth was approximately 2.5%, while organic growth was 4.1%. FX headwinds and net dispositions brought the growth rate down by 1.6%. I'll address our revenue growth in more detail in a few slides. From an earnings perspective, our agencies had another excellent quarter. The ongoing initiatives that focus on efficiency improvements and streamlining our portfolio, combined with our individual agency's intense focus on cost control, resulted in EBITA increasing 4.5% to $433 million. The resulting EBITA margin was 12.4%, which was up almost 25 basis points over last year. Operating income or EBIT for the quarter increased 5.2% to $408 million, and margins increased just over 30 basis points to 11.7%. Looking at the items below operating income. Net interest expense for the quarter was $42.8 million, up $2.5 million from the third quarter of last year and up $2.1 million sequentially from the second quarter of this year. This increase is due to the accrual of contingent interest on a remaining convertible bond. During the measurement period in the quarter, the stock price crossed the threshold requiring us to pay contingent interest on the bond, and in accordance with GAAP, we accrued the potential interest to be paid through the next call date, which is July of 2014. On the tax front, our operating tax rate for the quarter was 33.6%, which is in line with our expectations for the full year. The reported rate was somewhat higher at 34.5% because certain of the merger-related costs are capitalized and nondeductible for tax purposes. Looking at income from our affiliates and income allocated to our minority shareholders. There were numerous ups and downs from a year ago, as well as currency variances in the quarter, with the aggregate effect being no change year-over-year. As a result of all of that, our total non-GAAP net income increased 6.8% to $218 million and net income available for our common shareholders increased by 6.5% to $212 million. The GAAP net income figures, which include the merger-related costs, was $196 million and $191 million, respectively. On Slide 3, we compute EPS. First, as a result of stock repurchases we've made over the past 12 months, our diluted share count was down about 8.6 million shares or about 3.2% to just under 260 million shares. As a result, our non-GAAP diluted EPS was $0.82, representing an increase of 10.8%. As I mentioned earlier, the costs through the third quarter related to the merger reduced GAAP EPS by about $0.08, down to $0.74 per share, which was flat compared to 2012. On slides 4, 5 and 6, we present the summary P&L and EPS information for the year-to-date period, but I'm going to leave those pages for you to read. On Slide 7, we take a closer look at our revenue performance. First, with regard to foreign exchange, on a year-over-year basis, the U.S. dollar strengthened against most of our major currencies in the quarter, except the euro and the Chinese yuan. The net result reduced revenue in the quarter by $21.7 million or about 0.6%. As a reminder, the majority of our costs are incurred in the same currency as our revenues. As a result, the FX impact on our revenue flows pro rata through to our earnings, thus having a negligible effect on our operating margins. Looking ahead, if rates stay where they are currently, we expect foreign exchange to be negative between 50 and 75 basis points in the fourth quarter. Revenue from acquisitions, net of dispositions, decreased revenue by $34.2 million in the quarter or about 1%. As we mentioned in July, we completed the sale of our recruitment marketing business in the second quarter, so the net decrease was in line with our projections. In terms of organic growth, we had a very good quarter. The growth rate accelerated to 4.1%, adding $140 million in absolute terms. This increase was driven by continuing very strong performance from our media businesses, especially in the United States and in Asia, further acceleration in our specialty health care businesses and the pharma sector overall. Another quarter of strong performance from our leading PR brands and then, geographically, good performance overall in U.S., the U.K. and Russia, as well as the emerging markets of Asia and Latin America. Turning to our mix of business on Slide 8. Brand advertising accounted for 47% of our revenue, and marketing services contributed 53%. As for their respective growth rates, brand advertising's organic growth was 4.8%, driven by the strong performance of our media businesses, offsetting a few larger client losses in advertising earlier in the year. Marketing services in aggregate was up 3.5%. And within marketing services, CRM was up 2.3%, primarily driven by increases in our field marketing and branding businesses; and continuing strong performance in public relations posted organic growth of 4.6%; and specialty communications increased 8.3%, again, primarily driven by the strong performance of our specialty health care businesses. On Slide 9, our geographic mix of business in the quarter was split 52% domestic and 48% international. Turning to Slide 10. In the United States, revenue increased $57 million or 3.2%. Organic growth was very strong, up 5% or $88 million. Again, media continued to lead our domestic growth, with most of our other disciplines and industries contributing positively as well. Acquisitions, net of dispositions, decreased revenue by $31 million or 1.8%. Again, this was driven primarily by the sale of our recruitment marketing business in the second quarter. International revenue increased $26.5 million or 1.6%. FX created a headwind causing a revenue decline of $22 million. Acquisitions, net of dispositions, decreased revenue by $3 million or about 0.2%, again related to the recruitment marketing business that we sold. And organic growth, which continues to improve although slowly and with quite a bit of variance by region, was positive at 3.1% adding $51 million. In our larger European markets, consistent with our performance in Q2, Russia and the U.K. continued to perform very well, while Germany and France were down. Although the Eurozone markets in aggregate were down 1.6% organically in the quarter, it was an improvement from the second quarter. In Asia Pacific, we had strong performances across most of the region, with very strong results in South Korea, Singapore, China, India, New Zealand and Vietnam. And the Middle East and Latin America turned in solid organic results as well. We've also provided 2 additional slides, slides 11 and 12, that present our geographic revenue by regional subsets: North America, Europe, Asia Pacific, Latin America and Africa and Middle East. It's obviously the same information, just organized differently, so I'll leave those for you to read. Slide 13 shows our mix of business by industry. As you can see, there were very slight changes in our mix of business year-over-year. In the quarter, we had good results in food and beverage; consumer products; pharma, as I mentioned before; retail and telecom. Turning to Slide 14. Our cash performance for the first 9 months of the year was outstanding. We generated a little over $1 billion of free cash flow, excluding changes in working capital. On Slide 15, the breakdown of our primary uses of cash for the 9 months included dividends to common shareholders of about $212 million. The year-over-year decrease reflected the acceleration of our normal early January dividend payment to December 31 of last year, and that was offset by our increase in the dividends paid per share. Dividends paid to minority interest shareholders were $81 million, and capital expenditures were $123 million. CapEx was down from last year, when we had several large office space build-outs. Acquisitions, including earn-out payments, net of the proceeds received from the sale of investments, totaled $89 million, and share repurchases, net of the proceeds received from stock issuances under employee share plans, totaled $492 million. As I believe most of you already know, we have suspended our stock repurchase activity since the announcement of the merger. So on a net basis, for the 9 months, our uses of cash effectively equaled the cash generated in the business. Slide 16 shows our current capital structure. As you may recall, we redeemed $407 million of our convertible notes during the second quarter. As a result, our total debt at September 30 declined to just over $4 billion. Our net debt position at the end of the quarter increased slightly, up $30 million from a year ago to $2.52 billion. As a result, our total-debt-to-EBITDA ratio decreased to 1.9x, while our net-debt-to-EBITDA ratio is 1.2x. It stayed unchanged from this point last year. And our interest coverage ratio is 10.6x. Obviously, all the metrics are in good shape. And finally, on Slide 17, both our return on invested capital and our return on equity have continued to improve. For the past 12 months, our return on invested capital was 16.7% and our return on equity was just short of 30%. Well, that concludes our prepared remarks. There are several other supplemental slides included in the presentation materials that we'll leave for your review. And at this point, I'm going to ask the operator to open the call for questions.